Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · Real-Time Price · USD
1.980
-0.050 (-2.46%)
At close: Mar 6, 2026, 4:00 PM EST
2.030
+0.050 (2.53%)
After-hours: Mar 6, 2026, 7:47 PM EST

Kiora Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-8.543.59-12.51-13.58-13.77-6.86
Depreciation & Amortization
0.020.020.050.040.050.03
Stock-Based Compensation
0.830.660.750.460.840.72
Other Adjustments
-1.160.623.971.983.24-0.89
Change in Receivables
0.57-0.6----
Changes in Accounts Payable
0.470.23-0.810.78-0.310.14
Changes in Accrued Expenses
-2.573.28-0.460.610.04-0.14
Changes in Other Operating Activities
-1.650.76-0.55-0.72-0.77-0.31
Operating Cash Flow
-10.038.56-9.56-10.43-10.68-7.32
Capital Expenditures
0.01-0.01---0.06-0.02
Sale of Property, Plant & Equipment
---0.01--
Purchases of Investments
-14.71-35.63----
Proceeds from Sale of Investments
24.2612.98----
Payments for Business Acquisitions
-----0.09-0.11
Other Investing Activities
------0.11
Investing Cash Flow
9.56-22.66-0.01-0.16-0.24
Short-Term Debt Issued
2.25----0.28
Short-Term Debt Repaid
-2.25-----
Net Short-Term Debt Issued (Repaid)
-----0.28
Long-Term Debt Repaid
-----0.21-
Net Long-Term Debt Issued (Repaid)
-----0.21-
Issuance of Common Stock
0.2715.56.468.6417.84.72
Repurchase of Common Stock
----0.02--
Net Common Stock Issued (Repurchased)
0.2715.56.468.6217.84.72
Other Financing Activities
---0.5---
Financing Cash Flow
0.2715.55.978.6217.585
Effect of Exchange Rate Changes on Cash and Cash Equivalents
0.08-0.060.04-0.09-0.08-0.03
Net Cash Flow
-0.131.34-3.55-1.896.67-2.59
Free Cash Flow
-10.028.55-9.56-10.43-10.74-7.34
FCF Margin
-53.39%----60844.56%
Free Cash Flow Per Share
-2.392.07-17.76-128.16-400.89-575.28
Levered Free Cash Flow
-12.267.87-14.82-12.87-15.04-6.89
Unlevered Free Cash Flow
-13.357.14-14.45-11.5-15.09-7.19
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q